NCT05330143View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

May 15, 2024

Study Completion Date

May 15, 2024

Conditions
HIV-1-infectionHIV InfectionsPD-L1 Gene Mutation
Interventions
DRUG

ASC22 1mg/kg

ASC22 single-dose of 1mg/kg vials administered subcutaneously once 4 week.

DRUG

ASC22 2.5mg/kg

ASC22 single-dose of 2.5mg/kg vials administered subcutaneously once 4 week.

DRUG

Antiretroviral Therapy

standard antiretroviral therapy including Integrase inhibitors (INSTIs)

DRUG

Placebo

0.9% saline vials administered subcutaneously once 4 week.

Trial Locations (1)

100071

The Fifth Medical Center of the General Hospital of the Peoples Liberation Army, Beijing

Sponsors
All Listed Sponsors
lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY

NCT05330143 - Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV | Biotech Hunter | Biotech Hunter